EP0914160A2 - Mittel auf basis hydrophober cabomerkomplexe - Google Patents

Mittel auf basis hydrophober cabomerkomplexe

Info

Publication number
EP0914160A2
EP0914160A2 EP97920670A EP97920670A EP0914160A2 EP 0914160 A2 EP0914160 A2 EP 0914160A2 EP 97920670 A EP97920670 A EP 97920670A EP 97920670 A EP97920670 A EP 97920670A EP 0914160 A2 EP0914160 A2 EP 0914160A2
Authority
EP
European Patent Office
Prior art keywords
carbomer
powder
polymer
particles
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP97920670A
Other languages
English (en)
French (fr)
Inventor
Jean-Pierre Sachetto
Thomas Buser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tillotts Pharma AG
Original Assignee
Tillotts Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma AG filed Critical Tillotts Pharma AG
Publication of EP0914160A2 publication Critical patent/EP0914160A2/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • This invention relates to a hydrophobic powder of a complex, particularly bismuth carbomer and nicotine carbomer, pharmaceutical dosage forms, particularly enteric coated capsules containing said powder, its use in treating inflammatory bowel disease, and a method of preparing said hydrophobic powder.
  • Carboxypolymethylene polymers are widely used in the pharmaceutical industry as dispersing, emulsifying, suspending or thickening agents. Usually, they are high molecular weight polymers of acrylic acid cross-linked with allylsucrose or allyl ethers of pentaerithritol. A range of carbomers is available from B. F. Goodrich under the Trade Mark CARBOPOL.
  • EP-A-0 293 885 discloses a complex of carbomer and erythromycin which has the advantages of masking the bitter taste of the erythromycin and improving its systemic absorption.
  • the drug complex can be polymer coated with the most preferred being hydroxypropylmethycellulose phthalate.
  • Bismuth carbomer is useful for treating gastrointestinal disorders (see WO-A-9201457 ) and it has recently been found that nicotine carbomer is useful for treating inflammatory bowel disease ( PCT/GB97/00369 - unpublished ) .
  • the method of forming the hydrophobic powder provides a further aspect of the invention.
  • typical hydrophobising substances such as polyglycolyzed wax, sorbitan monostearate and cetylpyridinium chloride also formed lumps when applied to hydrophilic carbomer complexes.
  • the present invention provides a method of forming a readily water-dispersible composition of a hydrophilic carbomer complex which comprises coating particles of said complex passing a 150 ⁇ m sieve screen with a solution of a water-insoluble anionic polymer and drying the coated particles.
  • the present invention provides a pharmaceutical composition comprising a pharmacologically- acceptable hydrophobic powder of the invention.
  • the coating on the particles can be a partial or complete coating or the particles can be impregnated with the anionic polymer, such that the coated particle first disperses before it swells and coats the mucosa.
  • 100% of the hydrophilic carbomer particles pass a 100 ⁇ m sieve screen (i.e. they are sub 100 ⁇ m), more preferably at least 90%, especially at least 95%, of the hydrophilic carbomer particles pass a 63 ⁇ m sieve screen, more preferably a 50 ⁇ m sieve screen.
  • the precise particle size must be small enough to provide a composition with a suitable degree of hydrophobicity following coating with the anionic polymer. Preferred particle size may vary according to the nature and amount of the cation present in the complex and the nature and amount of the anionic polymer.
  • the presently preferred anionic polymers are anionic carboxylic polymers, i.e. polymers in which the anionic groups are at least predominantly free carboxylic and/or esterified carboxylic groups. It is particularly preferred that the anionic polymer is an acrylic polymer and the presently most preferred polymers are partly methyl esterified methacrylic acid polymers such as poly(methacrylic acid, methyl methacrylate) in which the ratio of free acid groups to ester groups is about 1:1 ((e.g. those availably from Rohm Pharma GmbH under the Trade Mark EUDRAGIT L), or especially, about 1:2 ((e.g. those availably from Rohm Pharma GmbH under the Trade Mark EUDRAGIT S ) . In this connection, selection of a particular anionic polymer and the amount thereof can provide the hydrophilic particles with a desired dissolution profile.
  • anionic carboxylic polymers i.e. polymers in which the anionic groups are at least predominantly free carboxylic and/or esterified carboxylic groups. It is particularly preferred that the ani
  • the amount of anionic polymer used will depend upon the nature and amount of the cation present in the salt, the nature of the impregnating anionic polymer, and the degree of hydrophobicity required. A suitable amount can be determined by simple experimentation but usually the anionic polymer will be present in an amount of 10 to 50%, preferably 20 to 40, more preferably 25 to 35 and especially about one third, based on the weight of the carbomer complex. Having regard to the small particle size the amount of polymer will be less than the theoretical amount required to coat the particles, and the swelling and dissolution of the carbomer will not be controlled by pH. For the avoidance of doubt the above % w/w also apply to the polymer used in the method of coating the particles.
  • an amount of water is present in the solvent/polymer mixture into which the carbomer particles are mixed.
  • the powder of the invention will be administered orally by loading into capsules, which usually will be coated to release the contents at the desired location in the gastrointestinal tract.
  • the capsules will be a soft or, preferably, hard gelatin capsule although other capsules which will dissolve in the required part of the gastrointestinal tract can be used.
  • the capsule When it is desired to administer the carbomer complex to the small intestine, the capsule can be coated with an enteric coating which will protect it during passage through the stomach. Any conventional enteric coating material which is soluble in the small intestine can be used but the coating should release its contents at a pH below the threshold value at which the impregnated powder ceases to be hydrophobic and readily dispersible. Suitable coating materials include cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate or initially ethyl cellulose followed by polyvinyl acetate phthalate, but it is preferred to use an anionic polymer having an appropriate dissolution profile. The presently preferred polymers are anionic carboxylic polymers.
  • the polymers should be acrylic polymers and the presently most preferred polymers are partly methyl esterified methacrylic acid polymers in which the ratio of free acid groups to ester groups is about 1:1 (e.g. Eudragit" L) .
  • the carbomer complex are active in the treatment or maintenance of inflammatory bowel disease.
  • Bismuth carbomer and nicotine carbomer are particularly preferred in accordance with the invention, especially for the treatment of inflammatory bowel disease.
  • carbomer complex herein includes salts such as metal salts of carbomer.
  • Capsules containing bismuth or nicotine or other carbomer complexes required to be administered to the large intestine preferably are coated with a coating which selectively dissolves in the large intestine or a specific area thereof.
  • the capsule coating is insoluble in gastric juice and in intestinal juice below pH 7 but is soluble in colonic intestinal juice whereby the coating remains substantially intact until the capsule reaches at least the ileum and, preferably, thereafter provides a sustained release of the drug in the colon.
  • the coating comprises a partly methyl esterified methacrylic acid polymers in which the ratio of free acid groups to ester groups is about 1:2 (e.g. EUDRAGIT" S).
  • the capsule coating can, and usually will contain plasticiser and possibly other coating additives such as colouring agents, gloss producers, talc and/or magnesium stearate as well known in the coating art.
  • plasticiser especially plasticiser especially triethylcitrate or diethyl phthalate.
  • an anionic polymers when used as the capsule coating, it can be used in admixture with neutral water-insoluble but permeable polymers.
  • the neutral insoluble but permeable polymers preferably are acrylic ester polymers, especially methylmethacrylate ester copolymers with ethylacrylate.
  • the molecular ratio of anionic polymer to neutral polymer is in the range 5:1 to 1:5, especially 3:1 to 1:3, most preferably 1:1 to 1:3.
  • hydrophobic powder according to the first aspect of the invention in the preparation of a medicament for the treatment of inflammatory bowel disease, particularly Crohn' disease and/or ulcerative colitis;
  • Preferred embodiments of the invention are as follows: - (a) an enteric coated capsule containing a hydrophobic powder comprising particles of bismuth carbomer or nicotine carbomer complex having a particle size which pass a 150 ⁇ m sieve screen which are coated with a partly methyl esterified methacrylic acid polymer at from 20 to 40% by weight of the carbomer complex;
  • an alkylcitrate such as triethylcitrate
  • a C [ _ 4 alcohol such as isopropanol
  • water is present with the polymer in the solvent/polymer mixture.
  • the bismuth particles are stirred into this mixture and the solvent then evaporated off under vacuum at between 40 to 80°C, most preferably between 50 - 70*C.
  • Bismuth carbomer (conventionally prepared from bismuth citrate and Carbopol" 974 P) containing about 15% w/w bismuth was milled (micronized) until 95% of the particles pass through a 50 ⁇ m sieve screen (99.9% ⁇ 98 ⁇ m, 80% ⁇ 10 ⁇ m ) .
  • Eudragit S 100 39.33 g
  • triethylcitrate 3.93 g
  • isopropanol 786.34 g
  • water 39.33 g
  • Micronized bismuth carbomer 131.07 g was slowly added whilst stirring continued. The mixture was then stirred at 50 °C under
  • the resultant hydrophobic impregnated powder contained about 30% EUDRAGIT" S and 5 to 10% moisture, thereby lowering the bismuth content of the powder to about 9.7 %w/w.
  • Nicotine carbomer (conventionally prepared from nicotine and Carbopol" 974 P) containing about 2% w/w nicotine was milled (micronized) until 95% of the particles pass through a 50 ⁇ m sieve screen.
  • Eudragit S 100 39.33 g
  • triethylcitrate 3.93 g
  • isopropanol 786.34 g
  • water 39.33 g
  • Micronized nicotine carbomer 131.07 g
  • the mixture was then stirred at 50 °C under -0.8 bar vacuum and the resultant vapour condensed.
  • the temperature was slowly raised to 70°C until no further vapour was produced.
  • the resultant powder was cooled to 20 °C and the vacuum released. Any lumps in the product were crushed and the powder kept under vacuum at 70 °C for 4 hours to dry.
  • a hydrophobic impregnated nicotine carbomer powder was produced.
  • Hard gelatin size 0 capsules (2,000) were each filled with 436.6 mg of the impregnated bismuth carbomer powder of Example 1 and 4.4 mg magnesium stearate (lubricant) and spray coated (50 mg/capsule) with an aqueous dispersion of EUDRAGIT" L containing: .
  • the aqueous dispersion was prepared as follows:
  • a first component was formed by stirring together triethylcitrate, Polysorbate 80 MO 55 F and Eudragit L 30 D-55.
  • a second component was prepared by heating some of the water (100 g) to 65 °C, adding monostearin and homogenizing to form an emulsion, which is cooled (15 mins) to room temperature whilst slowly stirring.
  • a third component was prepared by dispersing the talc in the remainder of the water (30 g).
  • the first component was filtered through a 105 ⁇ m filter; the filtrate stirred whilst slowly adding the second component via the same filter; and then the third component added while continuing stirring.
  • the coated capsule was resistant to 0.1N hydrochloric acid solution for 2 hours but rapidly disintegrated at pH 5.5 or above.
  • the dispersion of the powder following disintegration of the capsules was tested by two different methods. In the first method, each test capsule was placed on the surface of 100 cm° phosphate-buffer solution (pH 5.5, 6.0 or 6.5) at 37°C in a 250 cm 3 beaker stirred at 60 rpm by a magnetic stirrer. The times taken for capsule disintegration and content dispersion were observed. In the second method, each test capsule was subjected to the disintegration test described in US Pharmacopoeia XXII using a phosphate buffer solution (pH 5.5, 6.0 or 6.5) at 37°C.
  • the capsule coating should dissolve between pH 5.5 and 6.5.
  • Aqueous IM sodium hydroxide was slowly added to a gently stirred pH 6.5 phosphate buffer solution containing completely dispersed bismuth carbomer powder (following the disintegration therein of a capsule of Example 1 ) to raise the pH thereof and cause the powder to dissolve.
  • the viscosity of the solution rises as the concentration of bismuth carbomer and the pH increase as set forth in Table II below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP97920670A 1996-04-17 1997-04-14 Mittel auf basis hydrophober cabomerkomplexe Ceased EP0914160A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9607955.3A GB9607955D0 (en) 1996-04-17 1996-04-17 Hydrophobic carbomer salt compositions
GB9607955 1996-04-17
PCT/EP1997/001847 WO1997038726A2 (en) 1996-04-17 1997-04-14 Hydrophobic carbomer complex compositions

Publications (1)

Publication Number Publication Date
EP0914160A2 true EP0914160A2 (de) 1999-05-12

Family

ID=10792216

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97920670A Ceased EP0914160A2 (de) 1996-04-17 1997-04-14 Mittel auf basis hydrophober cabomerkomplexe

Country Status (6)

Country Link
EP (1) EP0914160A2 (de)
JP (1) JP2001509781A (de)
AU (1) AU2696597A (de)
CA (1) CA2251849A1 (de)
GB (1) GB9607955D0 (de)
WO (1) WO1997038726A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
ES2280835T3 (es) * 2002-12-19 2007-09-16 Pharmacia Corporation Formulacion no higroscopica que comprende un farmaco higroscopico.
ATE534373T1 (de) 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
CN116657439B (zh) * 2023-06-29 2024-09-17 浙江科技学院 一种pH响应型分散体系的高匀度碳纸原纸的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246037B2 (de) * 1972-09-20 1975-02-27 Taeschner & Co, 8831 Kipfenberg Peroral anwendbares Arzneimittel mit verzögerter Resorbierbarkeit in Suspensionsform
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
DK0540613T3 (da) * 1990-07-20 1996-04-01 Tillotts Pharma Ag Produkter og fremgangsmåder til behandling af fordøjelseskanalen
TW209174B (de) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
IT1256134B (it) * 1992-09-09 1995-11-29 Luigi Boltri Sali lipofili contenenti isotopi neutron attivabili e composizioni che li contengono
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9738726A2 *

Also Published As

Publication number Publication date
WO1997038726A2 (en) 1997-10-23
CA2251849A1 (en) 1997-10-23
AU2696597A (en) 1997-11-07
GB9607955D0 (en) 1996-06-19
JP2001509781A (ja) 2001-07-24
WO1997038726A3 (en) 1997-12-31

Similar Documents

Publication Publication Date Title
RU2201217C2 (ru) Таблетка с энтеросолюбильным покрытием и способ приготовления
DE69832731T2 (de) Arzneimittel mit magensaftresistentem überzug und methode zur herstellung
US4462839A (en) Enteric coating for pharmaceutical dosage forms
JP3660686B2 (ja) 腸溶性フィルム被覆材組成物、それを用いる被覆方法および被覆成形物
US5656290A (en) Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
CA1199869A (en) Preparation of aqueous alcoholic dispersions of ph sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DE69619668T2 (de) Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon
DE10332160A1 (de) Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
US20060159755A1 (en) Method for producing a controlled release preparation
JPS59193831A (ja) 腸溶性製剤の製造法
JPH07103015B2 (ja) ｐＨ制御膜コーチングを有する徐放性医薬製剤
DE2524813A1 (de) Verfahren zum beschichten von arzneimitteln mit darmloeslichen ueberzuegen
EP0914160A2 (de) Mittel auf basis hydrophober cabomerkomplexe
DE60026481T2 (de) Wässriges filmbildendes Überzugsmittel und oral anzuwendende feste Arzneizubereitung
WO1992001443A1 (en) Compositions containing microparticle matrices
EP0135829B1 (de) Flüssigkeit zum Herstellen darmsaftlöslicher Überzüge
US5492700A (en) Process and composition for the development of controlled release gemfibrozil dosage form
US20020015729A1 (en) Colonic delivery of weak acid drugs
AU2019250894B2 (en) Acidifying coatings and disintegration-resistant substrates coated therewith
AU2019334434A1 (en) Controlled drug release formulation
DE29824797U1 (de) Magensaftresistent überzogene Arzneimittel
US5358723A (en) Process and composition for the development of controlled release gemfibrozil dosage form
EP1784161A1 (de) Formulierung mit kontrollierter freisetzung mit tamsulosinhydrochlorid
WO1993010775A1 (en) Process and composition for the development of controlled release gemfibrozil dosage form
DE102004027924A1 (de) Arzneiform, enthaltend den Wirkstoff Cholylsarcosin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981019

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 19990903

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20000527